Skip to main content
Clinical Trials/EUCTR2013-001900-13-Outside-EU/EEA
EUCTR2013-001900-13-Outside-EU/EEA
Active, not recruiting
Not Applicable

A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection

AstraZeneca AB0 sites32 target enrollmentJune 5, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
hospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.
Sponsor
AstraZeneca AB
Enrollment
32
Status
Active, not recruiting
Last Updated
12 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 5, 2013
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.) Male or female children ages \=3 months to \<18 years 2\.) Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed infection, and expected to require hospitalization until after the end of treatment (EOT) evaluations are completed 3\.) If female and has reached menarche, or has reached Tanner Stage 3 breast development (even if not having reached menarche), the patient is practicing appropriate birth control or is sexually abstinant 4\.) Likely to survive the current illness or hospitalization 5\.) Sufficient intravascular access (peripheral or central) to receive study drug.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 32
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\.) History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin, other ß\-lactam antibiotics 2\.) If female, currently pregnant or breast feeding or has a positive serum ß hCG pregnancy test 3\.) Receipt of a blood or blood component (e.g., red blood cells, fresh frozen plasma, platelets) transfusion during the 24\-hour period before enrolment 4\.) BMI outside the range (below the 5th percentile or above the 85th percentile) for height, age and weight except for children \< 2 years of age 5\.) Babies born prior to 37 weeks gestation (cohort 4 only).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.
CTIS2023-503948-13-00aboratorios Farmaceuticos Rovi S.A.90
Recruiting
Phase 1
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)
ACTRN12620001261909Ascil Australia Pty LTD16
Completed
Phase 1
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)
ACTRN12620000108910Ascil Australia Pty Ltd8
Completed
Phase 1
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor AntagonistHepatitis BOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseases
ACTRN12620001019998Gilead Sciences50
Completed
Phase 1
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesIdiopathic Pulmonary FibrosisRespiratory - Other respiratory disorders / diseases
ACTRN12620001141932Avalyn Pharma Pty Ltd38